• #22: Novo Nordisk's next gen weight loss drug

  • Feb 6 2025
  • Length: 13 mins
  • Podcast

#22: Novo Nordisk's next gen weight loss drug

Listen for free

View show details

  • Summary

  • Novo Nordisk, known for its obesity drugs Ozempic and Wegovy, reported strong profit and revenue for 2024, surpassing Wall Street expectations. However, the company expects slower sales growth in 2025 due to rising competition, particularly from Eli Lilly, and pricing pressures. Despite this, Novo Nordisk remains optimistic, citing continued strong demand for obesity treatments and its drug pipeline, including CagriSema and amycretin. The company’s stock experienced volatility, partly due to concerns about obesity drug demand and geopolitical factors like tariffs. While uncertain about global trade impacts, Novo Nordisk is confident in the long-term potential of its drugs.

    Hosted on Acast. See acast.com/privacy for more information.
    Show more Show less
Show more Show less

What listeners say about #22: Novo Nordisk's next gen weight loss drug

Average customer ratings

Reviews - Please select the tabs below to change the source of reviews.

Audible.com reviews

Amazon reviews
No Reviews are Available